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Abstract
Background: Gait dysfunction due to lower limb central paralysis, frequently involving drop foot, is a common
cause of disability in multiple sclerosis and has been treated with transcutaneous functional electrical stimulation
(FES). We provide here the first report of 4-channel semi-implantable FES of the peroneal nerve which has been
successfully used for rehabilitation in patients following stroke.
Methods: FES was implemented via a 4-channel semi-implantable closed-loop system (ActiGait®, ©Ottobock),
generating dorsiflexion in drop foot. Walking distance, gait symmetry (temporospatial gait analyses, Vicon Motion
Systems®), gait velocity (10 m walking test) and quality of life (SF-36 questionnaire) were measured to evaluate the
therapeutic benefit of this system in two patients with progressive MS.
Results: Walking distance increased from 517 to 1884 m in Patient 1 and from 52 to 506 m in Patient 2. Gait
velocity did not change significantly in Patient 1 and increased from 0.6 to 0.8 m/s in Patient 2. Maximum
deviations of center of mass from the midline to each side changed significantly after 3 months of stimulation
compared to baseline, decreasing from 15 to 12 mm in Patient 1 and from 47 to 37 mm in Patient 2. Both patients
experienced reduced pain and fatigue and benefits to quality of life. Adverse events did not occur during the
observation period.
Conclusion: We conclude that implantable 4-channel FES systems are not only feasible but present a promising
new alternative for treating central drop foot in MS patients.
Keywords: Functional electrical stimulation, Multiple sclerosis, Peroneal nerve, Central drop foot, Hemiparesis,
Rehabilitation, Gait, Gait improvement, Neuroprosthetics, Quality of life
Background
Multiple sclerosis (MS) is an autoimmune-mediated dis-
order leading to progressive neurodegeneration, with in-
creasing disability in many patients despite modern
treatment approaches. Although recent surveys have
demonstrated the importance of walking for MS patients
[1], gait dysfunction occurs in 80 % of all MS patients
after a 10 to 15 year disease duration [2], often due to
central paralysis of the lower limbs, and commonly in-
volving a drop foot. Gait disturbances can lead to fre-
quent falls [3] and a pathological compensatory gait [4].
Common treatment options such as walking aids, ankle
foot orthoses (AFO) to prevent forefoot floor contact
during the swing phase of walking, and pharmacological
treatments (such as the potassium channel blocker fam-
pridine and local or systemic antispastic therapy) show
only limited efficacy, with benefits only in individual
cases.
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Functional electrical stimulation (FES) was first pro-
posed in the 1960s as a stroke therapy [5]. It describes
application of an electric current to a nerve in order to
induce muscle contraction and thereby assist in per-
formance of a functional activity such as walking. The
ActiGait® System (details of the operation mode are de-
scribed below) was officially approved in Germany in
2007 for hemiplegia following ischaemic or hemorrhagic
stroke. Because the ActiGait System has been recently
introduced, many studies investigating its use have not
yet reached publication. We therefore enquired directly
with Ottobock, who reported that the device has been
implanted in approximately 400 post-stroke patients (ef-
fective July 2015), but that implantation for other indica-
tions remains rare.
Therapeutic success may be anticipated, however, in
upper motor neuron damage regardless of etiology [6].
Moreover, benefits have been reported in MS patients ei-
ther receiving surface FES [7–11] or by use of a 2-
channel implanted system that stimulates the two
branches of the common peroneal nerve [12]. Difficul-
ties reported by some of our patients in handling a sur-
face FES system, and sensory side-effects resulting from
external attachment of the electrodes, led us to investi-
gate whether the advantages offered by an implantable
system could include reduced sensory side-effects. We
provide here the first report of successful implementa-
tion of FES applied directly to the peroneal nerve via an
implanted 4-channel cuff electrode to aid dorsiflexion in
MS in two patients. Both patients, suffering from pro-
gressive disease and central drop foot, experienced con-
siderable improvement in gait physiology, with
significantly increased walking distance, as well as sig-
nificant enhancement of quality of life (QoL).
Methods
Participants
An electrode cuff for FES of the peroneal nerve (Acti-
Gait®, ©Ottobock) was implanted in two patients suffer-
ing from foot drop secondary to MS. Approval by the
local ethical review committee and informed consent re-
garding off-label use of the device was obtained
beforehand.
Patient 1
Patient 1 was a 53-year-old lady who was diagnosed
with MS in 2002 after developing right-sided hemi-
hypesthesia, and followed a relapsing-remitting
course. In retrospect, a transient sensory disturbance
caudal from dermatome T10 in 1992 was in fact the
first episode. A further episode, involving numbness
of the right foot, followed in 2002. A slowly advan-
cing, persistent mild paresis of the left leg affecting
dorsiflexion and eversion of the foot began in
December 2005. Ankle-twisting with increasing walking
distance limited her walking distance to 500 m. The pa-
tient also suffered from temporary episodes of general
fatigue. The disease evolved into a progressive course
without further symptom remission. The Expanded Dis-
ability Status Scale (EDSS) [13] score was 3.5/10. The
diagnosis of MS was supported by cerebral MRI lesions
and delayed somatosensory evoked potentials (SSEP).
Immunomodulatory treatment with Interferon beta-
1a (Avonex, Biogen Idec) was administered from
2003–2013, then discontinued following 8 years with-
out exacerbations and increasing needle phobia.
Symptomatic treatment of gait disturbance with Fam-
pridine retard 2x 10 mg (Fampyra, Biogen Idec) from
2011 led to a more fluent gait pattern and facilitated
stair climbing. Despite weekly physiotherapy, the drop
foot remained impairing and walking distance did not
improve. Because the movement limitations were only
debilitating over longer distances, an AFO or other
walking aid were not deemed to offer benefits out-
weighing their inconvenience.
At referral in April 2013, walking required consider-
able concentration, with frequent stumbling due to fore-
foot catching and ankle twisting, especially with
increasing walking distance. After walking 500 m, the
patient suffered from left leg pain. Neurological examin-
ation of motor skills revealed a mild distal left hemipar-
esis, particularly of the lower limb, with mild spasticity.
The passive dorsiflexion/plantar flexion range exceeded
30° with a leg-foot-angle of approximately 90° in max-
imum passive dorsiflexion in a stretched leg position.
Muscle strength in the left leg, rated according to the
British Medical Research Council (BMRC) criteria, was
as follows: hip flexion 4/5, knee flexion 4/5, other prox-
imal movements 5/5, ankle dorsiflexion 1/5, pronation
2/5, supination 4/5, plantar flexion 5/5. Sensory system
examination revealed hypesthesia of the left lower leg
and foot, with pallhypesthesia of 5/8 over the left and 8/
8 over the right malleolus, measured using a Rydel Seif-
fer tuning fork, Position-, temperature- and pain sensa-
tion were intact. Her gait pattern was spastic-ataxic but
narrow-based. The outer edge of the foot dropped dur-
ing the swing phase, with the forefoot dragging over the
floor with increasing walking distance. Mild spasticity of
the toes was present, with minimal ankle joint instability
and the gait was asymmetrical.
A four-week test phase with surface FES increased
walking distance and reduced effort on walking, but sen-
sory side-effects were not well-tolerated. We therefore
implanted an electrode cuff for FES of the left peroneal
nerve (ActiGait®, ©Ottobock) in September 2013. There
were no peri- or post-operative complications. After a
healing phase of 3 weeks, we activated the stimulation
system.
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Patient 2
Patient 2 was a 46-year-old man, diagnosed with MS
with a primary progressive course in 2007. He developed
a slowly deteriorating paresis of the right leg with a dis-
abling paresis of dorsiflexion (EDSS 6.5). With hindsight,
the first symptoms appeared in 1998, with right upper
limb weakness and numbness. Also of note is a spinal
disc herniation of lumbar disc 4/5 to the right side, sur-
gically treated in 2008.
On initial presentation in 03/2013, he reported a
walking distance-dependent physical fatigue with in-
creasing right leg weakness and forefoot catching,
with concomitant back, sacral, and pelvic pain. Con-
centration was necessary to avoid stumbling, and he
required a cane and an AFO as walking aids. Fatigue
limited walking distance to 50 m using the AFO, and
he was unable to walk without the AFO due to ankle
twisting with each step.
Clinical examination revealed mild right hemiparesis
and moderate lower limb spasticity with contracture
of the calcaneal tendon. Passive dorsiflexion/plantar
flexion range exceeded 30°, with a leg-foot-angle of
approximately 90° on maximum passive dorsiflexion
in a stretched leg position. Muscle strength in the
right leg, according to BMRC criteria, was as follows:
hip flexion 3/5, extension 4+/5, abduction and adduc-
tion 5/5, knee flexion 2/5, extension 5/5, ankle dorsi-
flexion 1/5, pronation and supination 2/5, plantar
flexion 4+/5. Sensory examination revealed no sensory
deficits in the lower limbs. His gait pattern was
spastic-ataxic with circumduction of the right leg, ini-
tial forefoot-floor-contact, and dropping of the fore-
foot and outer edge during the swing phase. After a
few steps, he began to drag his right leg, followed by
the onset of spasticity of the toes and instability in
the ankle and knee joints. As for Patient 1, MRI and
electrophysiological findings supported the diagnosis
of MS.
Immunomodulatory therapy was conducted with
Interferon beta-1b 0.25 mg/ml (Betaferon, Bayer Health
Care) every other day from diagnosis. He received no
antispastic treatment. A temporary treatment with Fam-
pridine retard 2x 10 mg (Fampyra, Biogen Idec) did not
improve walking with the cane and AFO.
Although we observed a clinical benefit following a 4-
week test phase with surface FES, the patient experi-
enced difficulties with exact electrode positioning, and
moreover, the electrodes were easily dislodged during
walking. Surface FES was therefore deemed unsuitable
for daily use, resulting in the decision to employ an im-
planted FES system for direct stimulation of the right
peroneal nerve. We implanted the ActiGait® system in
November 2013 without complications and activated it
5 weeks later.
FES system
ActiGait® (©Ottobock) is a semi-implantable closed-loop
FES system generating dorsiflexion in drop foot (see
Fig. 1). The system is adapted to individual gait phase
and velocity by registering the patient’s heel lift through
an externally placed heel switch. The control unit worn
around the patient’s waist receives this trigger signal
wirelessly and generates a variable electromagnetic field
in the coiled antenna, which is connected to it. Transcu-
taneous electromagnetic induction is used to transfer
the power and control signals to the implanted stimula-
tor, which generates the stimulation pulses in 4 inde-
pendent current sources. These impulses are then
delivered through a dual lumen cable to 4 circularly ar-
ranged sets of electrodes embedded within a 23 mm sili-
cone cuff. Each of the 4 channels can be controlled
independently of the other channels, thus enabling the
programmer to control the volume of tissue activated
within the nerve. The fascicles of the common peroneal
nerve can thus be selectively stimulated to trigger a bal-
anced dorsiflexion of the foot while avoiding stimulation
of sensory fascicles.
Assessment tools
Evaluation of gait symmetry, comprising walking dis-
tance measurement and gait velocity, as well as quality
of life (QoL), using the SF-36 questionnaire [14], were
Fig. 1 Components of the ActiGait stimulation system. The control
unit worn around the patient’s waist receives a trigger signal
wirelessly from the externally placed heel switch when heel lift is
registered. It generates a variable electromagnetic field in the coiled
antenna, which is connected to it. Transcutaneous electromagnetic
induction is used to transfer the power and control signals to the
implanted stimulator, which generates the stimulation pulses in 4
independent current sources. These impulses are then delivered
through a dual lumen cable to 4 circularly arranged sets of
electrodes within a 23 mm silicon cuff electrode, and selectively
stimulate the fascicles of the common peroneal nerve and thus
trigger balanced dorsiflexion of the foot
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performed before implantation of the electrode, after the
stimulation was first commenced (referred to as “activa-
tion day”), and again 3 months later.
We used the 3D-Kinematicsystem from “Vicon Mo-
tion Systems, Oxford UK” to capture the kinematics, re-
quired for gait velocity measurement and for calculation
of the patient’s center of mass to quantify gait symmetry.
Markers were placed on the head, trunk, and limbs in
accordance with the Plug-In Gait software package,
which corresponds with the clinical gold standard in gait
analysis. To avoid inclusion of acceleration and braking
phases in the gait velocity measurements, the walking
space provided for patients had a total length of 8 me-
ters, suitable for recording a walking distance of at least
4 meters. In order to maintain balance with an asymmet-
ric gait, trunk, limb and head movements may be
employed, stabilizing the gait by shifting the center of
mass [15]. The change in gait resulting from stimulation
can be quantified by calculating the shift in the patient’s
center of mass after stimulation. The motion capture
system allows the patient’s center of mass to be calcu-
lated, based on the position locations of the markers in
3-D space, thus providing a holistic view of the body as
a single moving system in equilibrium in the transverse
plane [16] and thereby a measurement of the effect of
the stimulation on gait. Total walking distance in meters
was measured in the clinic corridor. The patients were
asked to walk until they no longer felt able to continue.
Gait velocity was defined as speed over a distance of 10
meters, measured three times with and without stimula-
tion. Both examinations took place on different days to
avoid bias of results by fatigue. Gait velocity and gait
analysis were performed successively with a pause of at
least 30 min for recovery.
Statistics
T-tests were applied to provide a quantitative indicator
of the significance of the changes in the assessment
measures following stimulation treatment. The two mea-
surements of walking distance on activation day, first
without, then during stimulation, were compared with
the two measurements performed 3 months later. The
three measurements of gait velocity performed on acti-
vation day before stimulation was commenced were
compared with three measurements made 3 months
later during stimulation. The difference between these
values reflects both the efficacy of the device and the im-
provement made over the time of its use. Simulation
supports the validity of T-tests with low sample num-
bers, defined as N = 2 to 5. [17]. The QoL questionnaire,
completed before stimulation commencement and re-
peated following 3 months of stimulation treatment,
consists of 36 items, each rated on a scale from 0 to 100.
In order to provide an indication of whether QoL was
generally improved following treatment, each of the 36
items was taken as a separate indicator, providing 35° of
freedom.
We measured the maximum deviations of center of
mass to each side from the midline for each gait cycle
pre-operatively and 3 months post-operatively. For Pa-
tient 1, two gait cycles were completed at each assess-
ment (N = 4, including both sides), and Patient 2
completed 3 gait cycles (N = 6, including each side). The
absolute difference between the two sets of distance
measures was subjected to a T-test of the null hypothesis
that the deviations from the midline post-operatively did
not differ from those measured pre-operatively.
Results
Patient 1
In Patient 1, with stimulation switched on, balanced
dorsiflexion was obtained in the ankle joint without sen-
sory side-effects. Dorsiflexion was adequate to prevent
contact between the outer edge of the foot and the floor
during the swing phase. A plain stabilization of ankle
and knee joint during the stance phase was already ap-
parent on first activation of the system. Hyperflexion
tending to genu recurvatum no longer occurred. After
3 months, the patient reported an improvement in walk-
ing and an increased sense of security. With increasing
walking distance (more than 500 m), the benefits of
stimulation on walking became more evident. She dem-
onstrated a nearly symmetrical gait pattern under stimu-
lation. The drift to each side on gait analysis measured
post-operatively during stimulation differed significantly
from pre-operative measurements (one-sided paired T-
test: T = 5.24, p = 0.014) with an average decrease from
15 to 12 mm (Fig. 2). Moreover, it may be observed that
the centre of mass was more central post-operatively.
Without stimulation, her gait pattern remained nearly
unchanged compared with preoperatively, though the
ataxic component was less distinct.
Walking distance increased more than threefold from
517 m to 1884 m after 3 months of stimulation (orthotic
effect of FES). Moreover, the patient could walk 1075 m
when stimulation was turned off, suggesting a thera-
peutic effect of FES in addition (Fig. 3). Postoperatively,
walking distance was significantly increased with the
stimulation activated compared with off (one-sided
paired T-test: T = 14.3, p = 0.022). There was no signifi-
cant change in maximum gait velocity over 10 m (one-
sided paired T-test: T = 1.6, p = 0.13; Table 1).
Evaluation of QoL parameters using an SF-36 ques-
tionnaire revealed various improvements compared with
preoperative statements (one-sided paired T-test:
T = −3.2, p = 0.0015), especially pertaining to parameters
of physical as well as emotional health; in particular pain
and fatigue were reduced. The patient reported a marked
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change in general health (Fig. 4). Patient 1 has received
an invalidity pension since having bronchial carcinoma
in 1992, so effect on occupation was not assessed.
Patient 2
In patient 2, ankle stability improved markedly, and
walking was facilitated, including an ability to cover
longer distances. After 3 months, walking-dependent
pain had subsided. The patient was able to resume
his profession in food control, working in field service
3 days a week. Maximum walking distance improved
from 52 m preoperatively with an AFO to 506 m
after 3 months of using FES (Fig. 3). Postoperatively,
walking distance was significantly increased with the
stimulation activated compared with off (one-sided
paired T-test: T = 7.85, p = 0.040) and with an AFO in
the absence of stimulation (one-sided paired T-test:
T = 6.86, p = 0.046). A walking distance of 176 m
remained after turning the system off. The EDSS
score was improved by 0.5 points. Remarkably, the
patient was able to walk a distance of 46 m without
an AFO or FES 3 months after activation (Fig. 3).
Maximum gait velocity had increased from 0.6 to
0.8 m/s immediately after activation, persisting after
3 months of FES, and velocity during the on versus
off mode differed significantly (one-sided paired
T-test: T = − 8.9, p = 0.006; Table 1). The drift of cen-
ter of mass from the midline 3 months after
Fig. 2 Undulation of center of mass along the line of progression. To evaluate gait symmetry, we examined the undulation of center of mass
along the progression line with a temporospatial gait analysis. Preoperatively, the center of mass was located on the non-paretic side of the body,
and the position of the center of mass moved to the left and right sides with a great amplitude, with varying degrees of severity, in both patients.
In both patients gait symmetry increased after 3 months under stimulation, with less drift to both sides and a shift of the center of mass to the
center of the body while walking
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commencement of treatment showed a trend to a re-
duction in patient 2 (47 vs. 37 mm; one-sided paired T-
test: T = 2.44, p = 0.059).
SF-36 questionnaire evaluation demonstrated improve-
ments in physical and emotional health (one-sided
paired T-test: T = −1.7, p = 0.048). The patient reported
reduced pain and fatigue, and experienced fewer phys-
ical, health-related role limitations on resuming work
(Fig. 4).
Discussion
Dropping of the forefoot in the swing phase of gait can
cause stumbling and falling [18]. A central drop foot is
often accompanied by ankle instability simply during
standing, as well as in the stance phase of the gait, in-
creasing the risk of the ankle twisting, as commonly ob-
served clinically. Moreover, walking becomes effortful
and slow, potentially shortening walking distance [19,
20]. Degenerative joint or back pain due to compensa-
tory weight shift may develop in the long term, as ob-
served in Patient 1.
Patients with drop foot often depend on walking aids
such as an AFO, which acts passively as a cast. The main
disadvantage in using an AFO is that it does not cause
muscle contraction and can thus lead to further joint
immobilization. It also lacks the sensory feedback of
muscle contraction compared with FES. Moreover, spas-
ticity of the toe flexors, as experienced by Patient 2, can
cause pressure sores. FES via surface or implantable
electrodes offers a means of compensating for these is-
sues. The few studies reported evaluating implantable
FES systems found improvements in gait parameters and
QoL in post-stroke patients [21–23]. The ActiGait® sys-
tem has been employed in a number of studies to date,
and few adverse events have occurred [21, 24]. Although
the motor response is similar using surface compared
Fig. 3 Walking distance in longitudinal follow up. Walking distance under different conditions preoperatively, at activation day and after
3 months. Stimulation therapy led to increased walking distance in both patients. In patient 1 walking distance increased from 517 m to 1884 m
after 3 months of stimulation (orthotic effect of FES). Moreover, the patient could walk 1075 m when stimulation was turned off, suggesting a
therapeutic effect of FES in addition. Postoperatively, walking distance was significantly increased in patient 1 with the stimulation activated
compared with off (one-sided paired T-test: T = 14.3, p = 0.022). In patient 2 maximum walking distance improved from 52 m preoperative with
an AFO to 506 m after 3 months of using FES and to 176 m with AFO. Postoperatively, walking distance was significantly increased with the
stimulation activated compared with off (one-sided paired T-test: T = 7.85, p = 0.040) and with AFO in the absence of stimulation (one-sided
paired T-test: T = 6.86, p = 0.046). Remarkably, the patient was able to walk a distance of 46 m without an AFO or FES 3 months after activation
Table 1 Gait velocity under different stimulation conditions.
Table 1 shows gait velocities in patient 1 and patient 2 on
activation day and after 3 months. In patient 1 there was no
significant change in maximum gait velocity over 10 m (one-
sided paired T-test: T = 1.6, p = 0.13). In patient 2, however,
maximum gait velocity had increased significantly immediately
after activation, persisting after 3 months of FES, and on and off
mode also differed significantly at each time point (one-sided
paired T-test: T = − 8.9, p = 0.006)
Velocity [m/s] Patient 1 Patient 2
off on off off using AFO on
Activation day 1.7 1.7 – 0.6 0.8
After 3 months 1.4 1.5 0.6 0.8 0.8
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with implanted FES [12], the potential risks of surgery
may be outweighed by several advantages offered by im-
planted over surface FES. Firstly, the electrode cuff, with
its 4 channels placed circularly around the target nerve,
generates the required motor response more precisely
than surface stimulation. Because 4 potential channels
are available for treatment, an optimum balance between
dorsiflexion and eversion for the individual patient can
be achieved. In some cases, for instance, a better orth-
otic effect, with greater ankle joint stability, can be ob-
tained by distinct eversion. Secondly, the patient is not
required to apply the electrode to the leg, which takes
time, and moreover can be difficult to perform correctly,
as reported by patient 2. The use of an implantable sys-
tem could thus potentially lead to more consistent use
of the device, with a concomitant increase in the thera-
peutic effect. Thirdly, discomfort due to electrical stimu-
lation is minimal, because applying the current directly
to the nerve avoids stimulation of non-target nerves,
eliminating sensory side-effects, which cannot be
achieved using a skin- mounted electrode. FES with an
implantable multichannel system can therefore be more
comfortable, as experienced by patient 1.
We provide here the first report of an implantable 4-
channel FES system in patients with MS. A 2-channel
system was implanted in 46 patients with central drop
foot of mixed etiology, including 17 MS patients, and
provided promising results, which have thus far been
presented as preliminary findings [12]; gait performance
improvement was similar to that provided in the same
patients using a surface stimulation system. The method
of fixation, however, whereby the electrode is sewn dir-
ectly onto the nerve, resulted in considerable adverse ef-
fects, with temporary nerve dysfunction in 10 cases,
implant failure in 6 cases, and one infection resulting in
4 explantations [12]. The authors report improved re-
sults with reduced sutures [12], and preliminary long-
term findings were reported in a recent conference,
whose proceedings are not yet available [25]. The bene-
fits in terms of gait parameters, QoL, and fatigue reduc-
tion found in the few studies investigating surface FES in
MS patients were similar to those reported in stroke
studies [7–11]. Moreover, the approach compared favor-
ably with the current gold standard of AFO, both in
terms of subjective patient reporting and measureable
outcomes of improved walking distance and gait sym-
metry. These findings are consistent with randomized
controlled trials comparing AFO with implanted FES
post-stroke that demonstrated comparable improvement
in gait and QoL [26] as well as superiority of FES for
obstacle avoidance [27].
Our patients demonstrate that implantable FES can
lead to considerable improvements in gait parameters
and QoL. Over the short 3-month observation period,
the patients showed an orthotic effect as well as a re-
habilitation benefit on walking distance, and increased
walking distance impacted QoL considerably. The sec-
ond patient was able to walk over 500 m with the stimu-
lation system switched on, compared with 50 m before
implantation, enabling the patient to walk outside the
home and to resume employment. Both patients re-
ported decreased pain, which may result from reduced
abnormal joint loading due to pathological compensa-
tory gait patterns and effort in ambulation. In patient 1,
although the more balanced and centered gait pattern
was observable clinically, the improvement in gait sym-
metry measurement was less marked than in patient 2.
With temporospatial gait analysis, we sought to quantify
our clinical observations using a readily measurable
component of gait symmetry and found a small but
Fig. 4 Quality of life using SF-36 questionnaire. Different parameters of quality of life are presented with a radar chart. We see different patterns
of changes in both patients, but consistent improvements in both in physical, emotional and general health, absence of pain and benefits in
energy and fatigue. Bar charts show total scores of the SF-36 questionnaire with significant improvements compared to preoperative statements
in both patients (one-sided paired T-test; pt. 1: T = −3.2, p = 0.0015; pt. 2: T = −1.7, p = 0.048)
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nonetheless statistically significant reduction in drift of
center of mass to each side. In patient 1, the increase in
walking distance was the more pronounced improve-
ment. In patient 2, the more marked reduction in drift is
likely to be because this patient showed a more pro-
nounced asymmetry of gait before the intervention. The
difference in findings between these two patients, both
of whom reported gait improvement following stimula-
tion treatment, underlines the importance of using a
range of outcome measures in quantitative outcome
assessment.
Both patients experienced reduced fatigue despite be-
ing more active. Social factors also improved, possibly
due to increased self-sufficiency and participation,
resulting from increased mobility. The current standard
therapy for drop foot is an AFO. Our second patient re-
ported an improved walking experience over longer dis-
tances with FES in comparison with the AFO, resulting
in increased walking distance and gait symmetry. Recent
randomized controlled trials comparing AFO with FES,
including both surface as well as implanted FES in post-
stroke patients, showed FES to provide equivalent im-
provement in gait and QoL to AFO [26] and enhanced
obstacle avoidance ability [27]. In another study, stroke
patients evaluated surface FES in a structured interview
as generally superior to different kinds of AFO [28], but
MS patients only reported advantages from FES in terms
of increased walking distance, fitness and physical activ-
ity [29]. These findings are consistent with the state-
ments from our second patient, who used an AFO
before receiving FES.
After 3 months using the FES, the second patient was
able to walk a distance without technical assistance that
he could only achieve with the use of an AFO pre-
operatively. This improvement is consistent with find-
ings using surface FES, which show that stimulation may
lead to enhancement of motor cortex neuroplasticity
[30]. It is moreover likely that the regular muscle con-
traction brought about during the use of the FES led to
improvements in muscle strength, which do not occur
when the ankle is held in a fixed position with an AFO.
The progressive character of MS may be considered as
a critical difference between post-stroke and MS pa-
tients. However, patients who have suffered a stroke are
recognized to be at risk of further cerebrovascular events
due to the persistence of the underlying pathology, such
as arteriosclerosis or atrial fibrillation. Even if a further
episode leads to persisting or additional deficits, the pa-
tient may still benefit from assisted dorsiflexion of the
foot. If motor function of the ipsilateral leg diminishes,
ActiGait® allows adaptation of stimulation parameters,
for example to increase the amplitude of dorsiflexion.
Many MS patients also remain stable for long time pe-
riods due to new and effective immunomodulatory basis
treatment [31], and may therefore also be suitable candi-
dates to receive an implantable FES system. The disad-
vantages of surface over implantable FES, such as poor
tolerance of sensory effects, and difficulties with elec-
trode placement, thus support the use of implantable ra-
ther than surface FES, even in progressive disorders.
Conclusion
We conclude that implantable FES systems are a feasible
new option for treating central foot drop in MS patients.
We demonstrate improvements in gait parameters, and
reduction of pain and fatigue, as well as positive changes
in quality of life in two individuals suffering from pro-
gressive MS treated with an implantable device for FES
of the peroneal nerve. The 4 channel cuff FES system
appears to offer the recognized advantages of an im-
plantable system compared with surface stimulation and
moreover offers the possibility of achieving these bene-
fits with fewer side-effects and complications than those
encountered using a system in which the electrodes are
sewn directly onto the nerve. The success of the therapy
in this preliminary study paves the way for a larger trial
to evaluate the benefits and general safety of the
approach.
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